Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 21 February 2017


INDICATIONS AND USAGE Triacin-C is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease that occurs mostly in older adults, is limited to the lungs and often displays a characteristic imaging and histological appearance. Find out how to diagnose IPF and the latest interventions available for patients living with this burden.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

Advisory information


CONTRAINDICATIONS Triacin-C is contraindicated under the following conditions: Codeine sulfate is contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy.

Use In Newborn or Premature Infants This drug should not be used in newborn or premature infants.

Use In Lower Respiratory Disease Antihistamines should not be used to treat lower respiratory tract symptoms, including asthma.

Hypersensitivity To (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine.

Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (MAO) inhibitor therapy (see PRECAUTIONS - Drug Interactions).

Special warnings and precautions

PRECAUTIONS General: Triacin-C should be prescribed with caution for certain special-risk patients, such as the elderly or debilitated, and for those with severe impairment of renal or hepatic function, gallbladder disease or gallstones, respiratory impairment, cardiac arrhythmias, history of bronchial asthma, prostatic hypertrophy or urethral stricture, and in patients known to be taking other antitussive, antihistamine or decongestant medications.

Patients ' self-medication habits should be investigated to determine their use of such medications.

Triacin-C is intended for short-term use only.

Information For Patients: Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people.

Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not.

These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing.

Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression.

As a result, codeine is contraindicated in all children who undergo tonsillectomy and/or adenoidectomy.

Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression (see WARNINGS - Death Related to Ultra-Rapid metabolism of Codeine to Morphine).


Patients should be warned about engaging in activities requiring mental alertness such as driving a car, operating dangerous machinery or hazardous appliances.


Patients with a history of glaucoma, peptic ulcer, urinary retention or pregnancy should be cautioned before starting this product.


Patients should be told not to take alcohol, sleeping pills, sedatives or tranquilizers while taking Triacin-C. 4.

Antihistamines may cause dizziness, drowsiness, dry mouth, blurred vision, weakness, nausea, headache or nervousness in some patients.


Patients should be told to store this medicine in a tightly closed container in a dry, cool place away from heat or direct sunlight and out of the reach of children.


Nursing Mothers - refer to following section titled “Nursing Mothers.” (see WARNINGS - Death Related to Ultra-Rapid Metabolism of Codeine to Morphine).

This product should not be used by persons intolerant to sympathomimetics used for the relief of nasal or sinus congestion.

Such drugs include ephedrine, epinephrine, phenylephrine and phenylpropanolamine.

Symptoms of intolerance include drowsiness, dizziness, weakness, difficulty in breathing, tenseness, muscle tremors or palpitations.

Codeine may be habit-forming when used over long periods or in high doses.

Patients should take the drug only for as long, in the amounts, and as frequently as prescribed.

Drug Interactions: Triacin-C may enhance the effects of: 1.

Monoamine oxidase (MAO) inhibitors; 2.

other narcotic analgesics, alcohol, general anesthetics, tranquilizers, sedative-hypnotics, surgical skeletal muscle relaxants, or other CNS depressants, by causing increased CNS depression.

This product may diminish the antihypertensive effects of guanethidine, bethanidine, methyldopa and reserpine.

Drug/Laboratory Test Interactions: Codeine: Narcotic administration may increase serum amylase levels.

Carcinogenesis, Mutagenesis, Impairment Of Fertility: No adequate studies have been conducted in animals to determine whether the components of Triacin-C have a potential for carcinogenesis, mutagenesis or impairment of fertility.

Pregnancy: Teratogenic Effects - Pregnancy category C. Animal reproduction studies have not been conducted with Triacin-C.

It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

This product should be given to a pregnant woman only if clearly needed.

Teratology studies have been conducted with the three ingredients of Triacin-C. Pseudoephedrine studies were conducted in rats at doses up to 150 times the human dose; triprolidine was studied in rats and rabbits at doses up to 125 times the human dose, and codeine studies were conducted in rats and rabbits at doses up to 150 times the human dose.

No evidence of teratogenic harm to the fetus was revealed in any of these studies.

However, overt signs of toxicity were observed in the dams which received pseudoephedrine.

This was reflected in reduced average weight and length and rate of skeletal ossification in their fetuses.

Nursing Mothers: The components of Triacin-C are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known.

Because of the potential for serious adverse reactions in nursing infants from maternal ingestion of this product, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

(see WARNINGS - Death Related to Ultra-Rapid Metabolism of Codeine to Morphine).

Pediatric Use: Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme CYP2D6 or high morphine concentrations).

These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine.

Codeine is contraindicated for post-operative pain management in these patients (see WARNINGS - Death Related to Ultra-Rapid Metabolism of Codeine to Morphine and CONTRAINDICATIONS) As in adults, the combination of an antihistamine, sympathomimetic amine and codeine can elicit either mild stimulation or mild sedation in pediatric patients.

In pediatric patients particularly, the ingredients in this drug product in overdosage may produce hallucinations, convulsions and death.

Symptoms of toxicity in pediatric patients may include fixed dilated pupils, flushed face, dry mouth, fever, excitation, hallucinations, ataxia, incoordination, athetosis, tonic clonic convulsions and postictal depression, (see CONTRAINDICATIONS and OVERDOSAGE sections).

Use In Elderly (Approximately 60 Years Or Older): The ingredients in Triacin-C are more likely to cause adverse reactions in elderly patients.

Adverse reactions

ADVERSE REACTIONS (The most frequent adverse reactions are underlined.)

General: Dryness of mouth, dryness of nose, dryness of throat, urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration and chills.

Cardiovascular System: Hypotension, headache, palpitations, tachycardia, extrasystoles.

Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.

Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, anxiety, nervousness, tremor, irritability, insomnia, euphoria, paresthesias, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions, CNS depression, hallucination.

G.I. System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.

G.U. System: Urinary frequency, difficult urination, urinary retention, early menses.

Respiratory System: Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness, respiratory depression.

Usage information

Dosing and administration

DOSAGE AND ADMINISTRATION DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND RESPONSE OF THE PATIENT. Usual Dose: Teaspoonfuls (5 mL) Adults and children 12 years and older 2 teaspoonfuls (10 mL) every 4 to 6 hours, not to exceed 8 teaspoonfuls (40 mL) in 24 hours.

Children 6 to under 12 years 1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 4 teaspoonfuls (20 mL) in 24 hours.

Children 2 to under 6 years?

teaspoonful (2.5 mL) every 4 to 6 hours, not to exceed 2 teaspoonfuls

More information

Category Value
Authorisation number ANDA088704
Orphan designation No
Product NDC 54879-005
Date Last Revised 28-07-2015
RXCUI 996650
Marketing authorisation holder STI Pharma LLC
Warnings WARNING: Death Related to Ultra-Rapid Metabolism of Codeine to Morphine Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism (see WARNINGS - Codeine Phosphate - Death Related to Ultra-Rapid Metabolism of Codeine to Morphine).